Tendinopathy
Tendinopathy Market

Tendinopathy is a failed healing response of the tendon, with the haphazard proliferation of

tenocytes, intracellular abnormalities in tenocytes, disruption of collagen fibers, and a

the subsequent increase in the noncollagenous matrix.


Tendinopathy Epidemiology Segmentation in 7MM from 2018 to 2030


  • Total Incident Cases of Tendinopathy 
  • Gender-specific Incident Cases of Tendinopathy 
  • Type-specific Incident Cases of Tendinopathy 
  • Region-specific Incident Cases of Tendinopathy 


Tendinopathy Epidemiology Insights Observed in 2020


  • Gender-specific Incident Cases of Tendinopathy in the United States were found to be 8,344,118 in the male population whereas 3,576,051 cases were found to be in the female population in 2020.
  • Type-specific Incident Cases of Tendinopathy in the United States were observed to be 4,768,067 cases of Tendonitis/tendinitis and 7,152,101 cases of tendinosis.


Tendinopathy Market Insights


The tendinopathy market size was found to be USD 10,556 million in the 7MM in the year 2020.


Tendinopathy Market Drivers


  • Rising incidence
  • Research and development
  • Approval of pipeline drugs in the forecasted period
  • Preclinical models


Tendinopathy Market Barriers


  • Poor and delayed diagnosis
  • Misdiagnosis of the disease
  • Limitations associated with the current treatment


Tendinopathy Emerging Therapies


The emerging drugs in the Tendinopathy market are


  • Micronized DHACM
  • Amniotic Fluid Tissue
  • Secukinumab (AIN457)
  • Platelet-rich Plasma
  • Botulinum toxin A
  • Ortho-ATI, and several others


Tendinopathy Key Players


The key companies in the Tendinopathy market are 


  • MiMedx Group
  • R3 Stem Cell
  • Novartis Pharmaceuticals
  • The University of Wisconsin-Madison or General Electric
  • Ipsen
  • Orthocell Limited, and several others